Is Tixjibemap Sagavama Active Against Omercron?

In laboratory studies, this cocktail is less active against the b a one lineage of omekron. The fda very recently authorized and recommended a dose of tixjibemap sagavamam. We need to extend that access to people who don't have regular health care access. In addition to focusing on here in the us, we need to insure these therapies are available around the world.